Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells by Amandine Legat et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 19 December 2013
doi: 10.3389/fimmu.2013.00455
Inhibitory receptor expression depends more dominantly
on differentiation and activation than “exhaustion” of
human CD8 T cells
Amandine Legat 1, Daniel E. Speiser 1*, Hanspeter Pircher 2, Dietmar Zehn3,4 and Silvia A. Fuertes Marraco1
1 Clinical Tumor Biology and Immunotherapy Unit, Department of Oncology, Ludwig Center for Cancer Research, Lausanne University Hospital (CHUV), Lausanne,
Switzerland
2 Department of Immunology, Institute of Medical Microbiology and Hygiene, University of Freiburg, Freiburg, Germany
3 Swiss Vaccine Research Institute (SVRI), Epalinges, Switzerland
4 Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland
Edited by:
Vincenzo Bronte, Immunology Unit,
Italy
Reviewed by:
Nadege Bercovici, Centre National de
la Recherche Scientifique, France
Kia Joo Puan, Singapore Immunology
Network, Singapore
*Correspondence:
Daniel E. Speiser , Clinical Tumor
Biology and Immunotherapy Unit,
Department of Oncology, Ludwig
Center for Cancer Research of the
University of Lausanne, University of
Lausanne, Hôpital Orthopédique,
Niveau 5 HO-05/1553, Avenue
Pierre-Decker 4, Lausane CH-1011,
Switzerland
e-mail: doc@dspeiser.ch
Under conditions of chronic antigen stimulation, such as persistent viral infection and can-
cer, CD8 T cells may diminish effector function, which has been termed “exhaustion.”
Expression of inhibitory Receptors (iRs) is often regarded as a hallmark of “exhaustion.”
Here we studied the expression of eight different iRs by CD8 T cells of healthy humans,
including CTLA-4, PD1, TIM3, LAG3, 2B4, BTLA, CD160, and KLRG1. We show that many
iRs are expressed upon activation, and with progressive differentiation to effector cells,
even in absence of long-term (“chronic”) antigenic stimulation. In particular, we evaluated
the direct relationship between iR expression and functionality in CD8 T cells by using
anti-CD3 and anti-CD28 stimulation to stimulate all cells and differentiation subsets. We
observed a striking up-regulation of certain iRs following the cytokine production wave, in
agreement with the notion that iRs function as a negative feedback mechanism. Intrigu-
ingly, we found no major impairment of cytokine production in cells positive for a broad
array of iRs, as previously shown for PD1 in healthy donors. Rather, the expression of
the various iRs strongly correlated with T cell differentiation or activation states, or both.
Furthermore, we analyzed CD8 T cells from lymph nodes (LNs) of melanoma patients.
Interestingly, we found altered iR expression and lower cytokine production byT cells from
metastatic LNs, but also from non-metastatic LNs, likely due to mechanisms which are
not related to exhaustion.Together, our data shows that expression of iRs per se does not
mark dysfunctional cells, but is rather tightly linked to activation and differentiation. This
study highlights the importance of considering the status of activation and differentiation
for the study and the clinical monitoring of CD8 T cells.
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INTRODUCTION
Inhibitory co-receptors (iRs) encompass a group of molecules that
function within the immune synapse to inhibit T cell function,
opposite to co-stimulatory receptors (1). Over the last decade,
several iR members have been closely linked with the phenome-
non of T cell “exhaustion,” including PD1, CTLA-4, TIM3, LAG3,
CD160, and 2B4 (2–6). “Exhaustion” of T cells terms the gradual
reduction of cellular functions that occurs in CD8 T cells in con-
ditions of chronic antigen exposure. This has been first reported
in the prototypic LCMV mouse model of chronic infection with
LCMV clone 13, with many findings confirmed in other chronic
infections and cancer, in mice and in patients (HIV, HCV, EBV in
SLE) (2–11).
Current models link the “exhaustion” phenotype to a par-
ticular over-expression of several iRs, which are considered key
to the molecular signature of exhausted cells and are proposed
to co-regulate CD8 T cell exhaustion (4, 6, 8, 12, 13). As a
consequence, iRs are often referred to as “exhaustion markers”
(14–16). In previous studies, we observed that CD8 T cells in
melanoma metastases showed reduced function (low cytokine
production) and high level expression of several iRs, reminis-
cent of exhausted cells (5, 17). However, further analysis of
iR expression in human CD8 T cells from melanoma patients
and healthy individuals also showed that iR profiles can change
depending on the differentiation status, anatomical localization,
and antigen-specificity (18).
Positive expression of iRs such as PD1, CTLA-4, TIM3, LAG-
3, 2B4, CD160, and BTLA has been directly linked to reduced
cytokine production by T cells from cancer patients (including
reports from our group) or in the chronic LCMV mouse model of
“T cell exhaustion” and other viral infections (7, 13, 19–23). How-
ever, recent studies reported that PD1 expression in healthy donors
does not correlate with lower functionality, but rather correlates
with differentiation to effector memory phenotype (18, 24). And
recently, we showed that PD1 positive CD8 T cells in periph-
eral blood mononuclear cells (PBMC) of healthy donors and
melanoma-specific CD8 T cells in PBMC of melanoma patients
are not necessarily functionally impaired (25).
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While there is increasing evidence that the expression of iRs
can vary depending on activation and differentiation, this has not
been yet thoroughly investigated for several different iRs in human
CD8 T cells (1, 26). Critically, in view of the current assumption
that expression of iRs indicates “T cell exhaustion,” it must be
determined whether this equation holds true in general, including
both pathological and healthy contexts, or whether it is primarily
applicable to conditions of chronic antigen exposure.
In the present study, we aimed to determine the significance of
the expression of a broad panel of iRs in human CD8 T cells, and
investigate whether expression of iRs was primarily associated with
T cell dysfunction. To this end, we performed a thorough analysis
of iR expression in CD8 T cells from healthy individuals, during
the course of stimulation with anti-CD3 and anti-CD28 antibodies
(aCD3/aCD28), and taking into consideration the differentiation
status of the cells. Based on our previous studies and on the
reported molecular signature of T cell exhaustion (2–5,7,8,12,27),
we focused on the following eight iRs: PD1 (and its ligand PDL1),
CTLA4, LAG3, TIM3, CD160, 2B4, KLRG1, and BTLA. We inves-
tigated the dynamics of expression of several iRs as well as possible
correlations with increased or decreased cytokine production. In
addition, blood-derived CD8 T cells were compared to CD8 T
cells from metastatic and normal lymph nodes (LNs) of melanoma
patients. Conclusively, we find that iR expression is predominantly
impacted by the differentiation as well as the activation status of
the cells, with more modest changes observed in both normal
and metastatic LNs. More strikingly, CD8 T cells that are positive
for iRs are not necessarily less capable of cytokine production,
but rather, expression of certain iRs can positively correlate with
differentiation status and with several standard activation markers.
MATERIALS AND METHODS
PERIPHERAL BLOOD AND LYMPH NODE SAMPLES
Peripheral blood from healthy donors was obtained from
leukocyte-rich preparations provided by the Blood Transfusion
Center of Lausanne, Switzerland. Peripheral blood as well as
metastatic [tumor-infiltrated lymph node (TILN)] and non-
metastatic (normal) LNs were obtained from melanoma patients
following surgery and upon written informed consent based on
the study protocol approved by the ethical commission of the Uni-
versity of Lausanne. The material originated from the following
patients: LAU309 (PBMC, TILN), LAU478 (PBMC, two non-
metastatic LNs), LAU1127 (PBMC, three non-metastatic LNs),
LAU1299 (PBMC, TILN), and LAU1413 (PBMC, 2 TILNs). Cell
suspensions of LN samples were prepared mechanically, in absence
of digestion enzymes, after finely mincing surgery specimens with
scissors directly in complete medium (composition described
below). PBMC from healthy donors and patients were obtained
following density gradient fractionation of blood samples using
Lymphoprep™. All samples were immediately cryopreserved in
RPMI 1640 supplemented with 40% FCS and 10% DMSO until
the experiment was performed.
CELL CULTURE AND STIMULATIONS
The Complete Medium used was RPMI 1640, complemented with
10% heat-inactivated FCS, 1% non-essential aminoacids (Gibco),
1% l-glutamine (Gibco), Hepes (10 mM), and 10,000 U/ml of
penicillin/streptomycin (Gibco). Of note, no cytokines nor growth
factors were added. For short-term stimulations (up to 24 h), CD8
T cells were stimulated in isolation. Where indicated, isolated
CD8 T cells were obtained by positive selection using the Dyn-
abeads® Human CD8+ selection (Invitrogen), according to the
manufacturer’s protocol except the use of anti-human CD8 anti-
body at 30% to minimize co-purification of CD8+(int) NK cells.
For longer-term treatments (>24 h), total PBMC were used given
the susceptibility of isolated CD8 T cells in culture in absence of
stimuli (=medium controls). No exogenous IL-2 was used in the
cultures and stimulations in this study. N.B. unlike CD4 T cells,
isolated CD8 T cells do not produce IL-2 in absence of stimulus and
therefore addition of exogenous IL-2 is required for the survival
of isolated CD8 T cells longer than 24 h (particularly “medium”
controls); in contrast, whole PBMC cultures do not require exoge-
nous IL-2. Isolated CD8 T cells or PBMC were cultured at a density
of 0.75–1× 106 cells/ml/cm2 in flat-bottom plates. For experi-
ments using patient-derived CD8 T cells (of limited availability),
U-bottom plates were used for stimulations were less than 50,000
purified CD8 T cells were available. In experiments using LN-
derived CD8 T cells, total cell suspensions (from TILN, normal
LN, or PBMC) were allowed to rest overnight in culture in com-
plete medium (without IL-2), prior to CD8 T cell isolation and the
4 h stimulation assay. Anti-CD3 and anti-CD28 (aCD3/aCD28)
beads were prepared using the “T cell expansion” kit (Miltenyi
Biotec), coated with the antibodies according to the manufac-
turer’s protocol. Stimulation with anti-CD3 and anti-CD28 beads
was performed at a 1:1 ratio with cells. When several time-points
were assessed, reverse kinetics were used, treating cells at different
times before the simultaneous analysis of all samples. For intra-
cellular staining of cytokines as well as CTLA-4, Brefeldin A was
added at 10µg/ml during the last 4 h of culture. For CD107a stain-
ing, the antibody was added to the cultures during the last 4 h of
stimulation.
FLOW CYTOMETRY
Data acquisition was performed with a Gallios flow cytometer
(Beckman Coulter, 3-laser configuration) with antibody pan-
els limited to 10-colors. The data was processed with FlowJo
(Tree Star Inc., v9.5.2) software and co-expression analyses were
obtained using SPICE software (v5.3) (28). The anti-human anti-
bodies used were anti-CD8 (APC-Alexa750, clone B9.11, Beckman
Coulter), anti-CCR7 (Brilliant Violet, clone G043H7, Biolegend),
anti-CD45RA (ECD, clone 2H4LD11LDB9, Beckman Coulter),
anti-CD16 (Krome Orange, clone 3G8, Beckman Coulter), anti-
TNFa (intracellular, Alexa700, clone Mab11, BD Biosciences),
anti-IFNg (intracellular, PE-Cy7 and PE with clone 4SB3, APC
with clone B27, BD Biosciences), anti-IL-2 (intracellular, PerCP-
Cy5.5, clone MQ1-17H12, BD Biosciences), anti-Granzyme B
(intracellular, FITC, clone GB11, Biolegend), anti-CD107a (PE,
BD Biosciences, clone H4A3), anti-human PD1 (PerCP-eF710,
clone eBioJ105, eBioscience), anti-human PDL1 (PE-Cy7, clone
MIH1, eBioscience), anti-CTLA-4 (intracellular, PE or APC, clone
BNI3, BD Biosciences), anti-TIM3 (PE, clone 344823, RnD),
anti-LAG3 (Alexa488, clone 17B4, AbD Serotec), anti-CD160
(Alexa647, clone BY55, eBioscience), anti-2B4 (PE-Cy5.5, clone
C1.7, Biolegend), anti-KLGR1 (A488, clone 13F12F2, provided
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by H. Pircher), anti-BTLA (PE-Cy7, clone BTLA7.2, Beckman
Coulter, or PE, clone J168-540, BD Biosciences), anti-4-1BB
(intracellular, PE-Cy7, clone 4B4-1, Biolegend), anti-CD25 (PE-
Cy7, clone BC96, Biolegend), anti-CD38 (Alexa700, clone HIT2,
eBioscience), and anti-CD69 (FITC, clone FN50, BD Biosciences).
All steps were performed at 4°C. Surface staining was performed
using antibodies in FACS buffer (PBS with 5 mM EDTA and 0.2%
BSA) for 30′. Dead-cell exclusion was done after surface staining
using the fixable dead-cell markerVivid-Aqua (Molecular Probes®,
Invitrogen). Cells were fixed overnight in 1% formaldehyde. Intra-
cellular staining was performed using antibodies in FACS buffer
with 0.1% saponin for 30′ at 4°C.
Of note, conditions for the detection of the various makers
(iRs and activation) were optimized relative to intracellular ver-
sus surface staining, as well as presence or absence of Brefeldin A
(necessary for cytokine intracellular retention and staining) (data
not shown). CTLA-4 detection is optimal when performed intra-
cellularly and is enhanced by Brefeldin A treatment of the cells in
culture. Brefeldin A abrogates de novo CD69 surface expression
but does not affect previously existing surface CD69 (i.e., it is pos-
sible to add Brefeldin A during the last 4 h of culture in mid- to
long-term stimulations). 4-1BB is efficiently detected on the sur-
face of activated cells; however, presence of Brefeldin A abrogates
surface 4-1BB and imposes its intracellular staining.
QUANTIFICATIONS AND STATISTICAL ANALYSES
Quantifications were made based on the softwares FlowJo, Graph-
pad Prism, and SPICE. For each marker, the analysis was based
on visible positive and negative populations, and isotype-matched
controls were used to verify positivity and used to set the gates
(isotype samples were set <1% positive, with 1% considered
background staining). For the analysis of cytokine production
within iR positive cells versus iR negative counterparts, only pop-
ulations >3% where considered; e.g., LAG-3 positive cells were
not analyzed; nor Naïve cells that are PD1 positive or EMRA
cells that are 2B4 negative (populations equal or below 3% are
marked as NA, not applicable). For statistical comparison of pie
charts, the built-in test in SPICE software (v5.3) was used (using
10,000 permutations) (28); other p-values were obtained using the
statistical tests as detailed in the figure legends, with ns, not sig-
nificant; *p< 0.05; **p< 0.01; ***p< 0.001. Where shown, error
bars indicate standard error of the mean.
RESULTS
INHIBITORY RECEPTOR (iR) EXPRESSION IN HUMAN CD8 T CELLS IS
INHERENTLY DIFFERENT IN NAÏVE VERSUS DIFFERENTIATED SUBSETS
For a detailed investigation of iR expression and correlations with
cytokine production, we used CD8 T cells isolated from PBMC
of healthy individuals. Based on CCR7 and CD45RA markers, we
identified Naive (CCR7+ CD45RA+), CM (CCR7+ CD45RA−),
and effector cells (CCR7−). The latter were split into Effector
Memory (EM CD45RA−), RAint (CD45RAint), or EMRA (EM
CD45RA+) cells (gating strategy detailed in Figure S1 in Supple-
mentary Material). We found that several iRs were particularly
upregulated with differentiation: PD1, 2B4, KLRG1, CD160, and
to a lesser extent, TIM3 (Figure 1). The opposite was seen for
BTLA, which was predominantly expressed by Naive cells. Notably,
there can be considerable differences amongst different donors
(Figure 1B). Nevertheless, our data clearly show strong differences
of iR expression depending on the differentiation status of human
CD8 T cells, in agreement with previous studies (18, 23, 24).
T CELL ACTIVATION CAN INDUCE DRASTIC CHANGES IN iR
EXPRESSION IN HUMAN CD8 T CELLS
We then performed a kinetic study, in which we activated purified
CD8 T cells with aCD3/aCD28 beads for various time-points, and
analyzed iR expression in combination with IFNg and TNFa as
functional readout.
Of note, only non-naive cells showed co-expression of multiple
effector molecules, including Granzyme B, IFNg, TNFa, IL-2, and
CD107a translocation upon stimulation (Figure S2 in Supplemen-
tary Material). Cytokine production occurred within the first few
hours of stimulation, with a peak at 2–6 h. Concomitant analysis
of the expression of iRs in Non-Naive cells showed that activation
induced clear changes already early on: CTLA-4, LAG3, and the lig-
and PDL1 were absent in resting cells (medium control) but were
clearly upregulated with activation, while PD1 and BTLA were
already present and modulated up (PD1) or down (BTLA) during
activation (Figure 2). In contrast, the levels of the other receptors
(KLRG1, 2B4, CD160, and TIM3) remained stable within the 24 h
of stimulus. When the various subsets were analyzed separately
(Figure 2C; Figure S3 in Supplementary Material), the extent of
up-regulation of iRs varied depending on the differentiation, with
CM cells showing more marked changes and EMRA cells show-
ing rather stable expression. Hence, changes were stronger in early
differentiation stages, where iRs were low in the resting state.
Intriguingly, the changes in iR expression were more marked at
the later time-points, when the cells stopped cytokine production
(from 16 h) (Figure 2). Therefore, we next extended the kinetics of
activation up to 72 h (Figure 3). Indeed, several iRs were strongly
upregulated. In correlation with the development of a homo-
geneous blast population of activated CD8 T cells (CD45RA−
CCR7−), by 72 h, cells uniformly expressed high levels of PD1 and
its ligand PDL1, CTLA-4, LAG3, and TIM3, while they lost expres-
sion of 2B4 and KLRG1, and remained low for CD160. Only BTLA
showed variable levels. Thus, CD8 T cell activation can drastically
change the levels of certain iRs, albeit with varying kinetics and
magnitude.
EXPRESSION OF iRs DOES NOT ALWAYS INDICATE LOWER T CELL
FUNCTION BUT RATHER CORRELATES WITH T CELL DIFFERENTIATION
In the light of the general concept that iR expression indicates
“exhaustion,” we investigated the potential of iR positive cells
to produce cytokines. Further to the changes in iR expression
observed during stimulation of CD8 T cells (Figures 2 and 3), the
focus of our study was therefore to determine whether iR positive
CD8 T cells are less functional than their iR negative counter-
parts; whether positive iR expression marks dysfunctional CD8 T
cells. To address this, we split populations into iR positive cells
and iR negative counterparts, and subsequently quantified IFNg
and TNFa production within each iR positive or negative group.
In addition, we distinguished various populations, including total
CD8 T cells, non-naive cells, or each individual differentiation
population (Figure 4A).
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FIGURE 1 | IR profiles change with CD8T cell differentiation. Resting
CD8 T cells isolated from healthy donor PBMC were analyzed for the
indicated inhibitory receptors (iRs) (these samples correspond to the
medium controls from the experiments in Figure 2). Three examples are
shown. (A). CCR7 versus CD45RA-based differentiation plot of total CD8 T
cells and off-set overlay histograms for each iR comparing the
differentiation subsets, gated as shown in detail in Figure S1 in
Supplementary Material. Three representative donors are shown.
(B). Quantification of A shown as percentage positive within each subset
(N =5).
The analysis on IFNg and/or TNFa production is shown using
pie charts (SPICE-based, Figure 4B) or total cytokine-producing
cells (Figure S4 in Supplementary Material). Crucially, we found
very distinct results depending on the population considered.
For instance, considering total CD8 T cells, BTLA positive cells
clearly produced less cytokines than BTLA negative cells. However,
this difference was greatly diminished when only non-naive cells
were taken in consideration, and there was no difference between
BTLA positive or BTLA negative cells when each individual
differentiation subset was analyzed separately. The opposite obser-
vation was true for KLRG1 and 2B4, which strongly and positively
correlated with higher cytokine production in total cells, but again
these differences were largely diminished or absent within individ-
ual differentiation subsets. Conversely, iR negative cells appeared
less cytokine-productive only when particular subsets were consid-
ered such as CM for CTLA-4. Although the expression of CD160
is generally very low (except in EMRA), it clearly marked less func-
tional cells particularly in the EM/RAint subset. For PD1 positive
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FIGURE 2 | Dynamics of iR expression relative to the cytokine
production wave within 24 h of stimulation. CD8 T cells isolated
from healthy donor PBMC were analyzed at different time-points after
stimulation with anti-CD3 and anti-CD28 antibodies and analyzed for
the various iRs together with TNFa and IFNg, as indicated (N =5).
(A). One representative example of the analysis, done as in Figure 1A.
(B). Quantification showing the percentage positive cells for each iR,
together with IFNg and TNFa, within total non-naive CD8 T cells (NB.
Naive cells do not produce cytokines – Figure S2 in Supplementary
Material). (C). Grouped quantification for the iRs that showed
up-regulation, in Non-Naive cells or the various differentiation subsets
as indicated.
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FIGURE 3 | Dynamics of iR expression over 3 days of stimulation. PBMC
from healthy donors were stimulated for different time-periods with anti-CD3
and anti-CD28 antibodies. CD8 T cells were analyzed similarly to Figure 1 for
the various iRs. (A). CCR7 versus CD45RA-based differentiation plot and FSC
versus SSC plot of total CD8 T cells, as well as off-set overlay histograms for
each iR comparing the various subsets as indicated. In order to analyze iRs
during the development of an activated blasting population, we used a
constant quadrant gating, based on the medium sample, for CCR7 and
CD45RA. Despite the fact that the gating is obsolete by 72 h, this highlights
the development of a homogeneous blast expressing various iRs. One
representative example is shown. (B). Quantification showing the percentage
positive cells for each iR (N =5).
versus negative cells, there were no major differences observed,
except in the consideration of total cells, where PD1 positive cells
were slightly more functional (only significance observed), which
again rather correlates with the fact that PD1 is mostly expressed
by more differentiated subsets (that produce more cytokines).
Within the various differentiation subsets, only a trend was seen
toward less cytokine in PD1 positive cells (Figure S4 in Supple-
mentary Material). These results confirm previous observations
for PD1 positive cells in healthy donor CD8 T cells (24, 25), where
no significant association between PD1 expression and cytokine
production was found, and provide parallel new evidence for the
remaining seven iRs that were hereby analyzed. Overall, cytokine
production in iR positive versus negative cells largely changed
depending on the consideration of differentiation subsets; and
iR positive cells were not less functional than iR negative counter-
parts, except for CTLA4 in CM and for CD160. In addition, it is
of interest to note that there was substantial inter-donor variabil-
ity, as it appears particularly evident from the pairings between iR
positive and negative counterparts shown in Figure S4 in Supple-
mentary Material (considering total cytokine-producing cells).
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FIGURE 4 | Positive expression of iRs does not necessarily mark lower
cytokine production but can rather correlate withT cell differentiation.
CD8 T cells from healthy donors were stimulated with anti-CD3 and anti-CD28
beads for 4 h, similarly as in Figure 2 (N = 15). (A). Analysis strategy to
compare iR positive versus negative cells, depending on CD8 T cell
differentiation. Total CD8 T cells or each differentiation subset (as indicated)
was split into iR positive and iR negative cells, which were subsequently
analyzed for cytokine production. (B) Pie charts showing the cytokine
production in iR positive or negative cells, considering either in total CD8, in
Non-Naïve, or in each of the differentiation subsets, as indicated in each row.
Pie arcs and slices represent the percentage positive for IFNg and/or TNFa, as
indicated in the legend. The numbers adjacent to the iR positive pies, above
and to the left of each pie, indicate the % of iR positive cells within the
differentiation gate considered. An empty gray circle means the population
does not apply (i.e., only populations representing iR expression gates >3%
were considered). The p-values shown apply to the comparison of iR positive
versus iR negative counterparts (indicated in between pairs of pies that
showed significance).
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SEVERAL iRs STRONGLY CORRELATE WITH ACTIVATION MARKERS
In view of the strong up-regulation of a number of iRs includ-
ing PD1, CTLA4, TIM3, LAG3, and PDL1 with activation, and
especially following the cytokine production wave, we sought to
investigate the correlation between iR expression and activation
markers. Strikingly, at 24 h of stimulation, up-regulation of PD1,
CTLA4, and TIM3 clearly correlated with up-regulation of the
activation markers 4-1BB, CD69, CD25, and CD38 (Figure 5). By
48 h, the co-expression of iRs and activation markers was more
pronounced. Furthermore, iR+ CD8 T cells showed even more
pronounced activation than their iR− counterparts (Figure 5B).
Of note, PD1+, CTLA4+, and/or TIM3+ cells largely represent
PDL1+ and LAG3+, all of which are co-expressed largely upon
activation (Figure 5C). These data show that multiple iRs are co-
expressed and positively correlated to T cell activation, suggesting
that iR positivity could in fact indicate the cells that best responded
to stimulation.
LYMPH NODE LOCATION, IN ADDITION TO THE TUMOR
MICROENVIRONMENT, CAN INFLUENCE THE EXPRESSION OF iRS AND
CYTOKINE PRODUCTION BY CD8 T CELLS
The phenomenon of “T cell exhaustion” has been described in
the particular context of chronic antigen stimulation. In cancer,
it is primarily within the tumor microenvironment that CD8 T
cells have been shown to over-express iRs, in correlation with
lower cytokine production. Therefore, we assessed the relationship
between iR positivity and cytokine production, taking in consid-
eration the differentiation subsets, in human CD8 T cells isolated
from metastatic LNs of melanoma patients (TILN). In parallel,
as controls, we also isolated CD8 T cells from LNs of melanoma
patients that were not infiltrated with melanoma cells (hereafter
termed“non-metastatic LN”or“normal LN”). Isolated CD8 T cells
from TILN and normal LN were directly compared with blood of
healthy donors as well as blood from melanoma patients, in a 4 h
assay with aCD3 and aCD28 beads.
In contrast to the various subsets found in CD8 T cells from
PBMC, LN samples displayed a dual subset distribution, includ-
ing a naïve population and a non-naïve population; the non-naïve
population was predominantly in the CM subset in normal LNs,
and in CM or EM in TILN (Figure 6A; Figure S5A in Supplemen-
tary Material). For subsequent analysis, gating on non-naïve cells
was performed because: (1) the various subsets found in blood-
derived CD8 T cells could be missing in LNs, and (2) based on
Figure 4, it is critical to distinguish at least naïve from non-naïve
cells to compare the functionality of iR positive versus negative
counterparts.
Within non-naïve cells, particularly high levels of iRs such
as PD1, CTLA-4, and LAG-3, and decreased levels of KLRG1
and 2B4 were only found in some (but not all) TILN, in con-
trast to blood samples, and in agreement with previous reports
(Figures 6A,B) (5). Of note, there was great variability in iR
expression in TILN, where the sample showing lowest percent-
age of CM in non-naïve cells had higher PD1hi and CTLA-4
(Figures 6A,B; Figure S5B in Supplementary Material). Inter-
estingly, our data shows that CD8 T cells from normal LNs
may also display different iR expression as compared to blood-
derived CD8 T cells, with notably the presence of PD1hi cells
and increased levels of CTLA-4 (Figure 6B). Of note, this dif-
ference is not explained by the predominantly CM phenotype
in LN samples (Figure S5B in Supplementary Material). More-
over, cytokine production was also low in non-naïve CD8 T cells
from normal LNs, similar to TILN, and in contrast to blood-
derived CD8 T cells (Figure 6B; Figure S5C in Supplementary
Material). The fact that samples from normal LNs and TILN
showed predominantly a CM phenotype could in part explain
lower cytokine production as compared to non-naïve cells in
blood (Figure S5C in Supplementary Material). However, cytokine
production in LN samples still remained lower as compared to
blood-derived CM cells (analysis not shown) and the% of CM did
not correlate with cytokine production within the normal LN or
TILN groups (Figure S5C in Supplementary Material), pointing
toward other factors influencing lower cytokine production in LN
samples.
Pertinently, in order to address the functionality of CD8 T
cells that positively express iRs in the various anatomical loca-
tions, we focused on the question of comparing iR positive cells
versus negative counterparts, and considering non-naïve cells
(minimal requirement based on Figure 4). Importantly, associa-
tions between iR positive versus negative expression and cytokine
production were relatively similar across blood or LN groups
(Figure 6C); Nonetheless, in agreement with previous obser-
vations, PD1hi cells that were found uniquely in LN samples
(and were absent in blood) showed reduced cytokine produc-
tion as compared to PD1int or negative counterparts (Figure S6 in
Supplementary Material) (19, 29). The overall results are described
in Table 1 and further discussed below in more detail.
DISCUSSION
Expression of iRs by CD8 T cells is generally considered a hall-
mark of “T cell exhaustion.” Particularly in the context of chronic
antigen exposure, such as persistent viral infections and cancer,
expression of iRs has been tightly linked with lower cytokine
production.
The molecular mechanisms of T cell inhibition that are medi-
ated by the various iRs, and how these integrate in the complex T
cell signaling network, are only partially understood (1). Neverthe-
less, it is now recognized that T cell co-signaling is largely context
dependent and relies on a diverse array of co-stimulatory and co-
iRs that are spatiotemporally regulated and may have distinct or
over-lapping functions in T cell priming, activation, differentia-
tion, and memory responses (1). However, the relationships to
these aspects (activation, differentiation, memory) remain as yet
unknown or not determined for several iRs, particularly in human
CD8 T cells (1).
In this study, we performed a broad analysis on associations
between the expression of iRs and cytokine production in human
CD8 T cells. We therefore assessed whether iRs are always markers
of CD8 T cell dysfunction, by concisely analyzing whether CD8 T
cells positive for a given iR were more or less functional (cytokine-
productive) than their iR negative counterparts. There were sharp
differences in the expression of iRs amongst the various differen-
tiation subsets in human CD8 T cells (18). Cytokine production
was also variable depending on the differentiation subset consid-
ered. Critically, we found that iR positive CD8 T cells are not
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FIGURE 5 | Up-regulation of iRs during stimulation strongly
correlates with activation markers. Healthy donor PBMC were
stimulated for 24 and 48 h with anti-CD3 and anti-CD28 antibodies.
CD8 T cells were analyzed for co-expression of iRs and activation
markers in two separate panels (I and II). (A). Representative plot of
PD1, CTLA4 or TIM3 (x -axis) versus the four activation markers as
indicated, gating was on non-naive CD8 T cells. (B). Quantification of
the expression of activation markers in iR+ versus iR− counterparts
(N =5). (C). Co-expression of PD1, CTLA4, TIM3, PDL1, and TIM3 on
non-naïve CD8 T cells.
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FIGURE 6 | Continued
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FIGURE 6 | Expression of iRs and cytokine production in human CD8T
cells from metastatic and non-metastatic lymph nodes differ from
blood-derivedT cells. CD8 T cells isolated from PBMC of healthy donors
(N =5), PBMC of melanoma patients (N =5), non-metastatic LN (“normal
LN”) of melanoma patients (N =5) and TILN (N =4) were stimulated for 4 h
with aCD3 and aCD28 beads. (A). CCR7 versus CD45RA-based differentiation
plot of total CD8 T cells, as well as off-set overlay histograms for each iR
comparing Naïve and Non-naïve cells, as indicated. One representative
example is shown for each, i.e., PBMC of healthy donor, PBMC of melanoma
patient, and non-metastatic LN, and two distinct examples are shown for
TILN. Naïve cells are shown in white histograms and non-naïve cells in gray
histograms. (B). Quantification showing the percentage positive cells for each
iR as well as for IFNg and TNFa amongst the indicated sample groups.
p-Values were based on multiple comparisons using one-way ANOVA with
Bonferroni correction. (C). Analysis of the expression of TNFa and IFNg in iR
positive or negative cells, within non-naïve cells, amongst the indicated
sample groups. Pie arcs and slices represent the percentage positive for IFNg
and/or TNFa as indicated in the legend.
Table 1 | Summary on the expression of iRs and its link to cytokine production in CD8T cells, considering differentiation, activation, and
anatomical location.
iR: Changes of iR expression iR+ cells show less cytokine production
than iR− counterparts, considering:
With
differentiation
With
activationa
In normal
LNb
InTILNb Total cells
(≈artifactc)
Subsets (i.e., corrected
for differentiation)
Anatomical
location
PD1 Increased (+ in
effectors)
+++ Presence of
PD1hi
Presence of
PD1hi
Opposite!: IR+= slightly
more cytokines
No Trend in LN
CTLA-4 (Absent in steady
state)
++++ Increased Increased Yes (slightly) Yes in non-naive/CM Yes in HD PBMC;
trend in all other
locations
TIM-3 Increased in N
and EMRA
+++ Similar Can be
increased
Trend No Trend in patient blood
and TILN
LAG-3 (Absent in steady
state)
++++ Similar Can be
increased
NA NA NA
CD160 Increased (+ in
EMRA)
Stable Increased Similar Yes (note very low
fraction of iR+)
Yes Yes in blood; trend in
LN
2B4 Increased
(progressive+)
Stable or – Similar Decreased Opposite!: IR+=more
cytokines
No (iR+ slightly more
functional)
All locations similar
KLRG1 Increased
(progressive+)
Stable or – Similar Decreased Opposite!: IR+=more
cytokines
No (iR+ slightly more
functional)
All locations similar
BTLA Decreased
(progressive −)
Stable or + Slightly
increased
Slightly
increased
Yes No All locations similar
aFor every + or − sign= a change of expression in 20% of cells can be seen.
Orange=positive or increase (dark=with at least one +); Blue= negative or decrease (dark=with at least one −).
bCompared to blood.
c“Artifact” refers to the fact that the interpretation of functional differences in iR positive versus negative cells based on total cells is misleading, with an inherent
differentiation bias. For example, in total cells, BTLA-cells are more functional because they are highly enriched for differentiated effector cells, and not because BTLA
expression would be tightly associated with low functionality in those cells.
NA, not applicable.
Trend=non-significant tendency in this direction seen.
necessarily less functional than their iR negative counterparts, but
this may hold true provided that the differentiation stage is care-
fully taken into account. Subsets must be individually considered,
or for the least naïve cells should be distinguished from non-naïve
cells. Considering total cells, iR positive cells can appear more
or less functional than their iR negative counterparts, but this is
predominantly due to the inherent distinct expression of iRs and
cytokines amongst the differentiation subsets.
Associations between iR expression and cytokine production
were also investigated in the context of the TILN and non-
metastatic LNs. Table 1 shows an overview on the different
observations described for each iR. Prominently, differentiation
and activation had the strongest impact on iR expression. Out
of the eight iRs considered, five showed an increase and one a
decrease with differentiation, and five showed an increase and
two a decrease with activation (for full details refer to Table 1).
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In addition, both the CD8 T cells from metastatic and non-
metastatic LN tissues showed differences in the expression of iRs
and in cytokine production as compared to blood-derived CD8 T
cells. Certain iRs (PD1, CTLA-4, TIM-3, LAG-3) can be particu-
larly highly expressed in the tumor microenvironment (TILN),
but there was high variability. These alterations in TILN are
in agreement with previously described observations for TILN
or tumor-infiltrating lymphocytes (TIL) material in melanoma
patients (5, 19, 30), however, non-metastatic LN tissue had not
been included as a control in these studies. Intriguingly, in pre-
vious work we had observed that CMV-specific CD8 T cells were
less functional in metastatic as well as non-metastatic LN tissue,
in addition to the observation that Melan-A-specific cells were
impaired in melanoma lesions compared to blood, but can rapidly
re-acquire function ex vivo. However, iR expression was not con-
sidered at that time [iRs and“T cell exhaustion”were not described
in tumor immunology (17)]. Similarly, we more recently observed
that EBV-specific CD8 T cells showed alterations in their iR profile
in TILN compared to blood, similar to Melan-A specific CD8 T
cells, pointing toward an anatomical influence on iR expression
(5). Although we found comparable CD8 T cell dysfunction in
TIL and TILN (17), it is possible that the non-lymphoid tumor
microenvironment (i.e., TIL, enriched for tumor-specific CD8 T
cells) presents more severe changes in iRs compared to TILN.
Experimentally and clinically, it is much more difficult to obtain
healthy tissue controls and TIL. Also, whether decreased cytokine
production is due to the particular sample processing that is neces-
sary with solid tissue material (from LNs and other tissues, but not
with blood samples), particular subset distributions within LNs,
or whether it reflects genuine decreased function in LNs, is dif-
ficult to assess. Nevertheless, our results comparing TILN versus
normal (non-metastatic) LN suggest that altered iR and cytokine
expression is not necessarily unique to the tumor microenviron-
ment, but may be a general feature of lymphoid tissue compared to
peripheral blood. High PD1 expression in CD8 T cells (and other
iRs) may operate to limit self-tissue damage, similarly to the pro-
tection of vascular endothelium by the PD1:PDL1 axis as shown
during viral infection (31).
Due to the low production of cytokines in TILN and normal
LN, it was difficult to assess whether iR positive CD8 T cells are
less functional than their iR negative counterparts. Nevertheless,
in all tissues, a tendency toward less cytokines was found for non-
naïve CD8 T cells that were PD1 positive or high, CTLA-4 positive,
CD160 positive, while negative for 2B4 and KLRG1. For PD1, this
is in agreement with previous findings using CD8 T cells from TIL
material (19), as well as the functional deficiency seen particularly
in T cells expressing high levels of PD1 (29).
Importantly, a direct link between positive iR expression and
lower cytokine production was only found conclusively for CTLA4
and CD160, with only a tendency in this direction observed for
PD1 (i.e., three of seven iRs considered, Table 1). Furthermore,
there was substantial inter-donor variability (Figure S4 in Sup-
plementary Material). Our data do not support that iRs can be
considered general markers of decreased cytokine production,
with this notion being the exception rather than the rule in our
experiments. Instead, while anatomical location (LN versus blood)
can influence the expression of iRs as well as cytokine production,
our data clearly show that expression of iRs in human CD8 T cells
is primarily dictated by T cell differentiation as well as activation.
Interestingly, several reports have already suggested that iR
expression may not be directly or solely linked to impaired T
cell function. Specifically, PD1 expression correlated with posi-
tive T cell function or activation markers such as 4-1BB in breast
cancer and CD38 in HIV (14, 15, 32); the differentiation marker
CD127 and not “exhaustion markers” correlated with positive
prognosis in HCV infection (16); CD127 levels also correlated with
PD1, 2B4, CD160, and KLRG1 expression in HCV infection (33);
TIM3 expression correlated with effector memory phenotype in
active tuberculosis (34), or questions were raised regarding PD1 as
“exhaustion” marker in SIV infection depending on whether total
or memory T cell were considered (35). While we find that BTLA
exceptionally predominates in Naïve cells [Figure 1; (18, 23)], con-
cordantly, BTLA expression in TIL used for adoptive therapy of
melanoma patients is associated with better tumor regression (36).
More recently, the “exhaustion marker” value of PD1 and BTLA
has been alternatively reviewed in the context of both cancer and T
cell differentiation (37). Also, the concern that PD1 is not necessar-
ily a marker of T cell exhaustion was recently raised in the context
of Acute Friend retrovirus infection, where CD8 T cells upregulate
PD1 yet are highly cytotoxic and control virus (38). In the con-
text of HIV infection, co-expression of PD1 and CD160 was also
shown to discriminate between dysfunctional PD1hi CD8 T cells
(PD1+ CD160+) versus CD8 T cells that up-regulated PD1 as a
result of T cell activation (PD1+ CD160−) based on transcrip-
tional profiling (39). Very recently, in the SIV infection model, the
use of PD1 as a marker of exhaustion was questioned and found
not be reliable when total T cells were considered (35). In fact, in
the LCMV mouse model of “T cell exhaustion,” the evidence shows
that iRs are strongly upregulated in the early phases of both acute
and chronic LCMV infection in mice (12). Thereafter, only in the
chronic setting are the iRs maintained or further increased, while
CD8 T cells progress to resting memory in the acute setting. CD8
T cells derived from chronic or acute LCMV infections are funda-
mentally different in terms of their differentiation but also their
activation status. Yet the activation, effector, and acute component
of strong iR expression has been neglected in the consideration
of the T cell “exhaustion” model (4, 40), and only recently and
limitedly addressed (1, 8).
In addition, possible differences between the mouse and human
systems must be carefully considered. In particular, KLRG1 does
not correlate to PD1 expression in the exhaustion model of LCMV
infection in mice (13). Interestingly, KLRG1 does exert inhibitory
function in human CD8 T cells but not mouse cells (41, 42). The
importance of KLRG1 in mouse“exhausted”CD8 T cells is unclear.
It could be that KLRG1 expression does not correlate with CD8 T
cell exhaustion or that KLRG1-expressing CD8 T cells were deleted
during the chronic infection. We find that KLRG1 but also 2B4
[related to exhaustion in mice (13)] behaved very similarly in
our experiments using human CD8 T cells, correlating strongly
with more advanced T cell differentiation but poorly with lower
cytokine production.
It is important to note that we used CD3- and CD28-specific
antibodies for stimulation, coated on beads, at a 1:1 ratio with cells.
Lower doses of stimulus (e.g., 0.2 beads per CD8 T cell) resulted in
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generally diminished cytokine production, which made it difficult
to assess functionality in general. Nevertheless, comparing iR pos-
itive versus negative counterparts, the trends were very similar at
lower and higher bead-to-cell ratio (data not shown). Notably, we
did not use high doses of beads nor other overwhelming activatory
treatments such as PMA and ionomycin. This polyclonal setup
allowed, on the one hand, to optimally activate all subsets and all
cells independently of TCR specificity and functional avidity. On
the other hand, and critically, this broad T cell stimulus allowed
us to concisely assess and compare the functional potential of iR
positive versus iR negative CD8 T cells. This setup, however, does
not address the function nor immediate influence of iRs per se on
T cell function, differentiation, or activation. Moreover, the notion
that differentiation and activation primarily drive iR expression is
well compatible with the concept that iR–iR Ligand interactions
can negatively interfere with CD8 T cell function. Our experiments
did not address and our results do not exclude that iRs, triggered
by their ligands, inhibit CD8 T cells. There is no doubt that iR pos-
itive cells can be inhibited by stimulator or target cells expressing
their ligands, when interacting antigen-specifically in the context
of a physiological immune synapse (1, 43–45).
In chronic infection and cancer, iRs contribute to T cell inhibi-
tion and the stumbling blocks faced by T cell-based immunother-
apies (44). Preclinical and clinical studies have demonstrated the
usefulness of treatments with antibodies blocking iRs (46). For the
further development of such therapies, it is therefore important to
monitor iR expression and function of CD8 T cells, together with
the differentiation and activation status of the cells. We find that
iR positive CD8 T cells are not necessarily dysfunctional, but can
be more or less differentiated. Moreover, we showed a dramatic
up-regulation of certain iRs during T cell stimulation, following
the peak of cytokine production, and in tight positive correlation
with several activation markers. This emphasizes the notion that
expression of multiple iRs can be due to recent or ongoing CD8
T cell activation, and that expression of iRs may in fact mark the
cells that responded best to a given stimulus.
Interestingly, positive PDL1 expression in tumors is a good
prognostic indicator in some cancers, such as melanoma (47),
reflecting ongoing CTL responses (48) and better chances of suc-
cessful anti-PD1 therapy (49). In turn, PD1 is increased in Melan-
A-reactive CD8 T cells with progression of melanoma, although
the prognostic value of PD1 on CD8 T cells is less clear, with no
association to overall survival in melanoma or a positive prognos-
tic value in other types of cancers such as HPV-induced head
and neck cancer (50, 51). Using the prototypic LCMV mouse
model of T cell exhaustion, we recently showed that CD8 T cells
from chronic infection retain the “exhaustion” phenotype upon
transfer to naïve mice yet are capable of re-expansion and protec-
tion under re-challenge with acute LCMV infection (25). Within
this latter study, we already reported that PD1 positive CD8 T
cells in PBMC from healthy donors or melanoma patients are
not necessarily functionally impaired. In this study, we broaden
the observations to several iRs, in healthy donors and patients,
studying the link between iR expression and cytokine produc-
tion, and critically, considering activation, differentiation as well
as anatomical location. Altogether, these results and the aforemen-
tioned literature points toward a context-dependent expression of
iRs and that many “exhausted” or iR positive CD8 T cells retain
functional capacity, in support of the immunotherapeutic poten-
tial of blocking iRs. In controlled experimental systems where the
iR ligands are present (29, 52, 53), complement studies will ana-
lyze the functional consequence of blocking one or several iR–iR
ligand interactions.
Our present observations using human CD8 T cells highlight
that iRs are often misinterpreted as only “exhaustion markers,” in
a “guilty by association” reflex. While there is evidence for a clear
correlation between increased iRs and lower cytokine potential in
CD8 T cells under chronic antigen exposure (viral infection and
cancer), our data show that the direct link between iR expression
and lower cytokines is weak. Rather, activation and differentia-
tion are strong primary drivers of iR expression, and both factors
should be carefully taken into account within the study and clinical
monitoring of normal and pathological CD8 T cell functions.
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Figure S1 | Gating strategy for the analysis of human CD8T cells. (A). Gating
of total live CD8 T cells, based on size, doublet exclusion, and finally selection of
CD8+, Vivid (dead) negative and CD16 (NK marker) negative. (B). Gating of the
various differentiation subsets based on CD45RA and CCR7, as indicated.
Figure S2 | Non-naïve CD8T cells show poly functionality, in contrast to
the absence of cytokines and CD107a in Naïve cells. (A). Representative
plots showing CCR7 versus CD45RA in total CD8 T cells as well as IFNg and
TNFa within the various subsets during the 24 h kinetics of stimulation with
aCD3 and aCD28 beads. (B). Quantification (% positive) of the production of
IFNg, TNFa, IL-2, and Granzyme B as well as CD107a translocation in the various
CD8 T cell subsets from healthy donors stimulated for 6 h with aCD3 and aCD28
beads (N =5). These data correspond to the samples and complement the data
shown in Figure 2.
Figure S3 | Additional data on the dynamics of iR expression and
correlation to cytokine production depending on differentiation (in
complement to Figure 2B). The analysis described in Figure 2B is additionally
detailed for the various differentiation subsets (N =5).
Figure S4 | Additional data on the cytokine production in iR positive versus
iR negative counterparts, depending on CD8T cell differentiation (in
complement to Figure 4). The data described in Figure 4 is analyzed for total
cytokine-producing cells (a single parameter based on the % of IFNg and/or
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TNFa positive cells, N = 15). Pairing lines indicate iR positive and negative
counterparts within the same sample and gate. p-Values are based on repeated
measures ANOVA with Bonferroni correction.
Figure S5 | Additional data on the subset distribution as well as correlation
of various iRs and cytokines to the proportion of CM in the various sample
groups (in complement to Figure 6). The experiment and samples described
in Figure 6 were analyzed for subset distribution, shown in (A). Further analyses
addressed the relationship between the proportion of CM cells in the various
sample groups and the percentage of iR positive (B) or cytokine positive cells
(C). p-Values in brackets indicate Pearson correlations, performed either on all
samples or within individual groups of samples (indicated in each graph’s
legend). NA, not applicable, because samples fall below the detection limit
of 1%.
Figure S6 | High expression of PD1 cells can be found in metastatic (TILN)
and non-metastatic LN, in contrast to blood (in complement to Figure 6).
The experiment from Figure 6 was analyzed in particular detail for PD1
expression in Non-Naïve cells. (A). PD1 versus FS-area plot of Non-naive CD8 T
cells are shown to render the PD1hi population more visible as compared to the
off-set overlays shown in Figure 6A. One representative example is shown for
each, i.e., PBMC of healthy donor, PBMC of melanoma patient and
non-metastatic LN, and two distinct examples are shown for TILN.
(B). Quantification showing the percentage positive cells for PD1 or PD1 high,
in the form of dotted plots to see the samples below 1% that are excluded for
the analysis in C. p-Values were based on multiple comparisons using one-way
ANOVA with Bonferroni correction. (C). Analysis of the expression of TNFa and
IFNg in PD1 high, intermediate or negative cells, within non-naïve cells,
amongst the indicated LN groups. Pie arcs and slices represent the percentage
positive for IFNg and/or TNFa as indicated in the legend.
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